system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

National Task Force on Aids Drug Development

Date, time, and place. October 12, 1995, 8:30 a.m., Hubert H. Humphrey Bldg., rm. 800, 200 Independence Ave. SW., Washington, DC.

Type of meeting and contact person. Open task force discussion, 8:30 a.m. to 4:30 p.m.; open public hearing, 4:30 p.m. to 5:30 p.m., unless public participation does not last that long; Heidi C. Marchand or Kimberley M. Miles, Office of AIDS and Special Health Issues (HF–12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–0104, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), National Task Force on AIDS Drug Development, code 12602.

General function of the task force. The task force shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.

Open task force discussion. The task force will present, hear, and discuss recommendations made at previous meetings and discuss the future of the task force.

FDA is giving less than 15 days public notice of the advisory committee meeting because of the urgent need to address the potential risk of this disease to public health safety. The agency decided that it was in the public interest to hold this scientific discussion on October 12, 1995, even if there was not sufficient time for the customary 15-day public notice.

Agenda—Open public hearing. Interested persons may present information or views, orally or in writing, on issues pending before the task force. Those desiring to make formal presentations should notify the contact person before October 10, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

National Mammography Quality Assurance Advisory Committee

Date, time, and place. October 16, 1995, 10 a.m., and October 17 and 18, 1995, 9 a.m., Dupont Plaza Hotel, 1500 New Hampshire Ave. NW., Washington, DC. A limited number of overnight accommodations have been reserved at the Dupont Plaza Hotel. Attendees requiring overnight accommodations may contact the hotel at 202–483–6000 and reference the FDA Committee meeting block. Reservations will be confirmed at the group rate based on availability.

Type of meeting and contact person. Open committee discussion, October 16, 1995, 10 a.m. to 12 m.; open subcommittee discussions, 12 m. to 5 p.m.; open public hearing, October 17, 1995, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; open subcommittee discussions, October 18, 1995, 9 a.m. to 1 p.m.; open committee discussion, 1 p.m. to 3 p.m.; Charles K. Showalter, Center for Devices and Radiological Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3332, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), National Mammography Quality Assurance Advisory Committee, code 12397.

General function of the committee. The committee advises on developing appropriate quality standards and regulations for the use of mammography facilities.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 10, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the

approximate time required to make their comments.

Open committee discussion. On October 16, 1995, the committee will discuss a methodology of assessing the costs and benefits of the Mammography Quality Standards Act (the MQSA). On October 17, 1995, the committee will discuss facility inspection procedures and have a briefing by FDA on facility inspections to date. Copies of the "MQSA Facility Inspection Procedures" may be obtained by submitting a written request to John L. McCrohan at the address given above for the FDA contact person. On October 18, 1995, the committee will discuss the ongoing work of the three subcommittees: Access to Mammography Services, Physicists Availability, and Cost Benefit of Compliance.

Open subcommittee discussions. On October 16 and 18, 1995, the three subcommittees will meet concurrently. The subcommittees will discuss information that is necessary to make the determinations and subsequently prepare the reports mandated by the MQSA. Upon completion, the subcommittee reports will be reviewed by the committee prior to submission to the Secretary of Health and Human Services and Congress.

Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee)

Date, time, and place. October 25, 1995, 8:30 a.m., Hubert H. Humphrey Bldg., rm. 405–A, 200 Independence Ave. SW., Washington, DC.

Type of meeting and contact person. Open committee discussion, 8:30 a.m. to 10:30 a.m.; open public hearing, 10:30 a.m. to 11:30 a.m., unless public participation does not last that long; open committee discussion, 11:30 a.m. to 5 p.m.; Ronald F. Coene, National Center for Toxicological Research (HFT–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3155, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Ranch Hand Advisory Committee, code 12560.

General function of the committee. The committee shall advise the Secretary and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand Study by the Air Force and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the advisory committee is desirable.